ArticleHemodialysis international. International Symposium on Home Hemodialysis2025
Variations in Serum Albumin Levels Over Time in Patients Treated With Conventional Hemodialysis or Expanded Hemodialysis: A Cohort Study.
Article in Hemodialysis international. International Symposium on Home Hemodialysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Impact of albumin variability during the first year on prognosis in peritoneal dialysis patients.Scientific reports · 2026Article
- Expanded Hemodialysis with Theranova 500 Improves Dialysis Adequacy and Blunts Inflammation: A 24-Week Quasi-Randomized Trial.Journal of clinical medicine · 2025Article
- Variations in Serum Albumin Levels Over Time in Patients Treated With Conventional Hemodialysis or Expanded Hemodialysis: A Cohort Study.Hemodialysis international. International Symposium on Home Hemodialysis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionHypoalbuminemia is a well-established risk factor for mortality in chronic hemodialysis (HD) patients. To evaluate the association of time-varying serum albumin with the type of dialyzer, we analyzed serum albumin over time in two cohorts of HD patients, one receiving HDx therapy enabled by the Theranova dialyzer and the other conventional HD with high-flux dialyzer (HF-HD).
methodsIn this cohort study, 1092 prevalent adult HD patients (mean age 61 years; 62% men; 42% had diabetes; 19% had cardiovascular disease) at Renal Care Services Colombia undergoing either HDx therapy enabled by Theranova dialyzer (n = 559) or HF-HD (n = 533) were enrolled between September 1, 2017, and November 30, 2017, and then underwent repeated measurements of serum albumin for up to 48 months. Sociodemographic and clinical, and laboratory characteristics at baseline were recorded, and a repeated-measures analysis of variance (ANOVA) was conducted to examine differences in means of serum albumin at different time points. To evaluate the association between dialysis membrane and albumin levels during the follow-up, a linear panel regression analysis was performed, allowing control for imbalances in the cohorts of baseline clinical and demographic variables, as well as the time-dependent variables.
resultsMean albumin concentration remained above 3.8 g/dL and did not differ over time between HDx and HF-HD (p = 0.789). No association (p = 0.208) between serum albumin levels varying over time and the use of the Theranova dialyzer was found in the linear panel regression model. However, serum albumin was linked to both inflammatory and nutritional markers, including C-reactive protein, ratio of platelets to lymphocytes, and protein-energy wasting.
conclusionVariations in serum albumin levels over time were associated with protein-energy wasting, inflammation, high age, vascular access, and hospitalizations, but not with the type of dialyzer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.